SS-31
Also known as: Elamipretide
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) developed by Hazel Szeto (Cornell) and clinically advanced by Stealth BioTherapeutics. It concentrates in the inner mitochondrial membrane by binding cardiolipin. In September 2025, the FDA granted accelerated approval to elamipretide (brand name FORZINITY) as the first therapy for Barth syndrome — the first FDA-approved mitochondria-targeted drug. It remains investigational for other indications.
Pricing for SS-31
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
Average price
$4.69/mg
range $0.00–$20.00/mg
Sellers
56
from $0.00
45-day trend
+5.5%
vs 45-day avg $/mg
50 of 56 sellers have a current price· 35 stale listings hidden (not seen in 7 days)
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · just now
$2.25/mg -52% vs avg$1125
500mg
- 🇺🇸 Licensed Peptides95
✓ verified at source · just now
$2.00/mg -57.3% vs avg$99.99
50mg
- 🇺🇸 Reta One Labs95
✓ verified at source · just now
$3.40/mg -27.5% vs avg$34.00
10mg
99.2% purity 2 COAs - 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · just now
$5.40/mg +15.2% vs avg$270
50mg
99.8% purity 4 COAs - 🇺🇸 Hydro Research Peptides91
via Disclosed Labs · just now
$3.50/mg -25.4% vs avg$175
50mg
99.9% purity 3 COAs - 🇺🇸 Peptide Plugs89
✓ verified at source · just now
$2.60/mg -44.5% vs avg$130
50mg
- 🇺🇸 Ascension Peptides84
via Disclosed Labs · just now
$6.00/mg +28% vs avg$60.00
10mg
- Peptide Supply Co.83
via Disclosed Labs · just now
$1.25/mg -73.3% vs avg$625
500mg
- 🇺🇸 OROS Research79
via Disclosed Labs · just now
$3.67/mg -21.8% vs avg$110
30mg
99.0% purity 2 COAs - 🇺🇸 Texpeptide65
✓ verified at source · just now
$5.50/mg +17.3% vs avg$55.00
10mg
no purity - 🇨🇳 Qing Li Peptide64
✓ verified at source · just now
$0.00/mg -100% vs avg$0.00
10mg
no purity - 🇭🇰 zztai Peptide Ltd43
✓ verified at source · just now
$8.34/mg +77.9% vs avg$417
50mg
no purity - optimasupply.isUnscored
via Disclosed Labs · just now
$3.50/mg -25.4% vs avg$175
50mg
no purity - 🇺🇸 Alpha PeptidesUnscored
via Disclosed Labs · just now
$3.58/mg -23.7% vs avg$35.79
10mg
no purity - realpeptides.coUnscored
via Disclosed Labs · just now
$5.40/mg +15.2% vs avg$270
50mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
COAs for SS-31
116 third-party tests across 19 vendors. Each card links to the full report.
For
SS-31
by Ion Peptide· batch 2S10-06242026
For
SS-31
by Reta One Labs· batch SS100626
For
S-31
by Ion Peptide· batch SS3150-05042026
For
S-31
by Ion Peptide· batch SS3150-05042026
For
SS-31
by Ion Peptide· batch 2S10-05042026
For
S-31
by Ion Peptide· batch 2S10-05042026
For
SS-31
by Peptidegurus· batch cmojgr89m002r9grxu1x2sttx
For
SS-31
by Peptide Plugs· batch 121-A-D
For
SS-31
by Peptide Partners· batch SPL-3436
For
§-31
by Ion Peptide· batch §-3110-03242026
For
§-31
by Ion Peptide· batch §-3150-03232026
For
SS-31
by Forge Performance Co.· batch Blue Top
For
SS-31
by Qihang Peptide· batch 3
For
SS-31
by Glacier Aminos· batch MTP10GA-03
For
SS-31
by Mile High Compounds· batch SS3-010-MH-04
For
SS-31
by Ion Peptide· batch C3150-02272026
For
SS-31
by Orbitrex Peptides· batch MTP100326
For
SS-31
by Qihang Peptide· batch 2
For
SS-31
by Peptide Supply Co.· batch PSCSS3150001
For
SS-31
by Peptide Partners· batch SS202602
For
SS-31
by Peptide Partners· batch SS202602
For
SS-31
by Ion Peptide· batch SS3110-02032026
For
SS-31
by Licensed Peptides· batch LP02202016
For
SS-31
by Ion Peptide· batch SS3110-02032026
14 citations indexed for SS-31
animal · 2026
Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model
Background Exercise intolerance, promoted by skeletal muscle- and mitochondrial dysfunction, has been identified as a therapeutic target in heart failure with preserved ejection fraction (HFpEF).
Study · 2026
Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function
Membrane binding and aggregation properties of α-synuclein are closely associated with Parkinson's disease and a class of related syndromes named as synucleinopathy.
animal · 2026
Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury
Spinal cord injury (SCI) induces secondary damage characterized by mitochondrial dysfunction, oxidative stress, and apoptosis, which collectively impede neurological recovery. Elamipretide (SS-31) is a mitochondria-targeting peptide with potential neuroprotective effects.
animal · 2026
SS-31 improves the quality of maternally aged oocytes by ameliorating mitochondrial function and metabolism
Reproductive aging is closely associated with poor oocyte quality in vitro maturation, but effective approaches to ameliorate it have still not been fully determined. Here, we found that SS-31 supplementation efficaciously improved oocyte maturation and early embryonic development from aged mice.
Study · 2026
Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion
Background Ozone (O₃) exposure induces acute airway injury characterized by airway hyperresponsiveness (AHR) and airway mucus hypersecretion (AMH). Oxidative stress and mitochondria-derived reactive oxygen species (mtROS) are key contributors.
animal · 2026
SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization
Accumulating evidence suggests that ferroptosis and mitochondrial dysfunction contribute significantly to brain injury following cardiac arrest (CA) and resuscitation.